– USA, PA – Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of JJ Bienaimé to its Board of Directors, bringing over three decades of experience in the biotechnology and pharmaceutical industries, most recently serving as Chairman and CEO of BioMarin Pharmaceuticals.
“Immunome is pleased to welcome JJ to the Board of Directors as we enter our next stage of growth. JJ has a unique understanding of how to build a biotechnology company, and he shares our commitment to improving the lives of cancer patients. His guidance will be essential as we advance our pipeline of potential first-in-class and best-in-class targeted cancer therapies,” said CEO Dr. Clay Siegall.
About Jean-Jacques Bienaimé
Mr. Bienaimé currently serves as Chairman and CEO of BioMarin Pharmaceuticals, Inc., a position that he has held since 2005. Under Mr. Bienaimé’s leadership, BioMarin grew from a company with a single marketed treatment product to a multi-billion-dollar commercial organization with numerous approved products to treat rare diseases, increasing the company’s value from approximately $400 million to approximately $15 billion. It has been announced that Mr. Bienaimé will transition to retirement from his role as Chairman and CEO of BioMarin effective December 1, 2023. Before joining BioMarin, Mr. Bienaimé served as the Chairman, President, and CEO of Genencor, a targeted oncology biopharmaceutical company that was ultimately acquired in 2005 by Danisco. Before Genencor, Mr. Bienaimé held the positions of Chairman, President, and CEO of Sangstat Medical. During his time at Sangstat Medical, Mr. Bienaimé guided the company to profitability, before an eventual acquisition by Genzyme. Before joining Sangstat Medical, Mr. Bienaimé held various senior management positions at Rhone-Poulenc Rorer Pharmaceuticals and Genentech.
“I am excited to join the Immunome Board of Directors as they work to bring transformative oncology therapeutics to the patients most in need,” said JJ Bienaimé. “Throughout my career, pairing a patient-centric approach with operational excellence has been foundational to success, and I see that same mentality at Immunome. I look forward to enhancing Immunome’s ability to execute on Clay’s compelling vision.”
Mr. Bienaimé currently serves on the Board of Directors of Incyte Corp., a biopharmaceutical company focused on first-in-class treatments for serious unmet needs, the Pharmaceutical Research and Manufacturers of America Organization (PhMRA) and The Biotech Industry Organization (BIO). Mr. Bienaimé received his MBA from the Wharton School at the University of Pennsylvania and his undergraduate degree from the École Supérieure de Commerce de Paris.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, targeted effectors, radioligand therapies, and ADCs. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets.
SOURCE: https://immunome.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
